<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364055</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Guiding the starting dose of the once-daily formulation of tacrolimus in "<i>de novo"</i> adult renal transplant patients: a population approach.</ArticleTitle><Pagination><StartPage>1456565</StartPage><MedlinePgn>1456565</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1456565</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1456565</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="UNASSIGNED">The once-daily extended-release tacrolimus formulation (ER-Tac) has demonstrated similar efficacy and safety to the twice-daily immediate-release formulation (IR-Tac), but few population-based pharmacokinetic models have been developed in <i>de novo</i> kidney transplant patients to optimize doses. Therefore, this study aimed i) at developing a population pharmacokinetic model for ER-Tac in <i>de novo</i> adult kidney transplant patients ii) and identifying genetic factors and time-varying covariates predictive of pharmacokinetic variability to guide tacrolimus dosage during the early post-transplant period.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 1,067 blood tacrolimus concentrations from 138 kidney transplant patients were analyzed. A total of 29 out of 138 patients were intensively sampled for 24 h on the day 5 post-transplantation; meanwhile, for the remaining patients, concentrations were collected on days 5, 10, and 15 after transplantation. Tacrolimus daily doses and genetic and demographic characteristics were retrieved from the medical files. Biochemistry time-varying covariates were obtained on different days over the pharmacokinetic (PK) study. A simultaneous PK analysis of all concentrations was carried out using the non-linear mixed-effects approach with NONMEM 7.5.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A two-compartment model with linear elimination and delayed absorption best described the tacrolimus pharmacokinetics. Between-patient variability was associated with oral blood clearance (CL/F) and the central compartment distribution volume (Vc/F). Tacrolimus concentrations standardized to a hematocrit value of 45% significantly improved the model (<i>p</i> &lt; 0.001). This method outperformed the standard covariate modeling of the hematocrit-blood clearance relationship. The effect of the CYP3A5 genotype was statistically (<i>p</i> &lt; 0.001) and clinically significant on CL/F. The CL/F of patients who were CYP3A5<i>*1</i> carriers was 51% higher than that of CYP3A5<i>*1</i> non-carriers. Age also influenced CL/F variability (<i>p</i> &lt; 0.001). Specifically, CL/F declined by 0.0562 units per each increased year from the value estimated in patients who were 60 years and younger.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The 36% between-patient variability in CL/F was explained by CYP3A5 genotype, age, and hematocrit. Hematocrit standardization to 45% explained the variability of tacrolimus whole-blood concentrations, and this was of utmost importance in order to better interpret whole-blood tacrolimus concentrations during therapeutic drug monitoring. The dose requirements of CYP3A5<i>*/1</i> carriers in patients aged 60 years or younger would be highest, while CYP3A5<i>*/1</i> non-carriers older than 60 years would require the lowest doses.</AbstractText><CopyrightInformation>Copyright © 2024 Fernández-Alarcón, Nolberger, Vidal-Alabró, Rigo-Bonnin, Grinyó, Melilli, Montero, Manonelles, Coloma, Favà, Codina, Cruzado, Colom and Lloberas.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fernández-Alarcón</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nolberger</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal-Alabró</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigo-Bonnin</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biochemistry Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinyó</LastName><ForeName>Josep M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Medicine Unit, Department of Clinical Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melilli</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montero</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manonelles</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coloma</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Favà</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Codina</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruzado</LastName><ForeName>Josep M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Colom</LastName><ForeName>Helena</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lloberas</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nephrology Department, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CYP3A4</Keyword><Keyword MajorTopicYN="N">CYP3A5</Keyword><Keyword MajorTopicYN="N">ER-Tac</Keyword><Keyword MajorTopicYN="N">age</Keyword><Keyword MajorTopicYN="N">de novo-kidney transplant patients</Keyword><Keyword MajorTopicYN="N">hematocrit</Keyword><Keyword MajorTopicYN="N">population pharmacokinetics</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>11</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364055</ArticleId><ArticleId IdType="pmc">PMC11447946</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1456565</ArticleId><ArticleId IdType="pii">1456565</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abrantes J. A., Jönsson S., Karlsson M. O., Nielsen E. I. (2019). Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br. J. Clin. Pharmacol. 85 (6), 1326–1336. 10.1111/bcp.13901</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13901</ArticleId><ArticleId IdType="pmc">PMC6533430</ArticleId><ArticleId IdType="pubmed">30767254</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson B. J., Holford N. H. (2009). Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24 (1), 25–36. 10.2133/dmpk.24.25</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.24.25</ArticleId><ArticleId IdType="pubmed">19252334</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreu F., Colom H., Elens L., van Gelder T., van Schaik R. H. N., Hesselink D. A., et al. (2017). A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach. Clin. Pharmacokinet. 56 (8), 963–975. 10.1007/s40262-016-0491-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-016-0491-3</ArticleId><ArticleId IdType="pubmed">28050888</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews L. M., De Winter B. C., Van Gelder I., Hesselink D. A. (2016). Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. Pharmacogenomics 17 (16), 1737–1740. 10.2217/pgs-2016-0136</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pgs-2016-0136</ArticleId><ArticleId IdType="pubmed">27790923</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews L. M., Hesselink D. A., van Gelder T., Koch B. C. P., Cornelissen E. A. M., Brüggemann R. J. M., et al. (2018). A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin. Pharmacokinet. 57 (4), 475–489. 10.1007/s40262-017-0567-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-017-0567-8</ArticleId><ArticleId IdType="pmc">PMC5856873</ArticleId><ArticleId IdType="pubmed">28681225</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkali K., Rostaing L., Premaud A., Woillard J. B., Saint-Marcoux F., Urien S., et al. (2010). Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin. Pharmacokinet. 49 (10), 683–692. 10.2165/11535950-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11535950-000000000-00000</ArticleId><ArticleId IdType="pubmed">20818834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann T. K., Hennig S., Barraclough K. A., Isbel N. M., Staatz C. E. (2014). Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther. Drug Monit. 36 (1), 62–70. 10.1097/FTD.0b013e31829f1ab8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FTD.0b013e31829f1ab8</ArticleId><ArticleId IdType="pubmed">24089074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergstrand M., Hooker A. C., Wallin J. E., Karlsson M. O. (2011). Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13 (2), 143–151. 10.1208/s12248-011-9255-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-011-9255-z</ArticleId><ArticleId IdType="pmc">PMC3085712</ArticleId><ArticleId IdType="pubmed">21302010</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet M., van Gelder T., Åsberg A., Haufroid V., Hesselink D. A., Langman L., et al. (2019). Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther. Drug Monit. 41 (3), 261–307. 10.1097/FTD.0000000000000640</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FTD.0000000000000640</ArticleId><ArticleId IdType="pubmed">31045868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman L. J., Brennan D. C. (2008). The role of tacrolimus in renal transplantation. Expert Opinion on Pharmacotherapy. Expert Opin. Pharmacother. 9 (4), 635–643. 10.1517/14656566.9.4.635</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.9.4.635</ArticleId><ArticleId IdType="pubmed">18312164</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillard S., Moulin B., Buron F., Mariat C., Audard V., Grimbert P., et al. (2016). Advagraf(®), a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transpl. Int. 29 (8), 860–869. 10.1111/tri.12674</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tri.12674</ArticleId><ArticleId IdType="pubmed">26373896</ArticleId></ArticleIdList></Reference><Reference><Citation>Campagne O., Mager D. E., Tornatore K. M. J. (2019). Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities? J. Clin. Pharmacol. 59 (3), 309–325. 10.1002/jcph.1325</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1325</ArticleId><ArticleId IdType="pmc">PMC7395655</ArticleId><ArticleId IdType="pubmed">30371942</ArticleId></ArticleIdList></Reference><Reference><Citation>Davit B., Braddy A. C., Conner D. P., Yu L. X. (2013). International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J. 15 (4), 974–990. 10.1208/s12248-013-9499-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-013-9499-x</ArticleId><ArticleId IdType="pmc">PMC3787230</ArticleId><ArticleId IdType="pubmed">23821352</ArticleId></ArticleIdList></Reference><Reference><Citation>Holford N. H. G., Anderson B. J. (2017). Allometric size: the scientific theory and extension to normal fat mass. Eur. J. Pharm. Sci. 15 (109S), S59-S64–S64. 10.1016/j.ejps.2017.05.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2017.05.056</ArticleId><ArticleId IdType="pubmed">28552478</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson M. O., Sheiner L. B. (1993). The importance of modeling interoccasion variability in population pharmacokinetic analyses. J. Pharmacokinet. Biopharm. 21 (6), 735–750. 10.1007/BF01113502</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01113502</ArticleId><ArticleId IdType="pubmed">8138894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirubakaran R., Hennig S., Maslen B., Day R. O., Carland J. E., Stocker S. L. (2022). Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. Br. J. Clin. Pharmacol. 88 (4), 1751–1772. 10.1111/bcp.15091</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15091</ArticleId><ArticleId IdType="pubmed">34558092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirubakaran R., Stocker S. L., Hennig S., Day R. O., Carland J. E. (2020). Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin. Pharmacokinet. 59 (11), 1357–1392. 10.1007/s40262-020-00922-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-020-00922-x</ArticleId><ArticleId IdType="pubmed">32783100</ArticleId></ArticleIdList></Reference><Reference><Citation>Krämer B. K., Charpentier B., Bäckman L., Silva H. T., Jr, Mondragon-Ramirez G., Cassuto-Viguier E., et al. (2010). Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am. J. Transpl. 10 (12), 2632–2643. 10.1111/j.1600-6143.2010.03256.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2010.03256.x</ArticleId><ArticleId IdType="pubmed">20840480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloberas N., Elens L., Llaudó I., Padullés A., van Gelder T., Hesselink D. A., et al. (2017). The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenetics Genomics 27 (9), 313–322. 10.1097/FPC.0000000000000296</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FPC.0000000000000296</ArticleId><ArticleId IdType="pubmed">28704257</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z., Bonate P., Keirns J. (2019). Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. Br. J. Clin. Pharmacol. 85 (8), 1692–1703. 10.1111/bcp.13952</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13952</ArticleId><ArticleId IdType="pmc">PMC6624387</ArticleId><ArticleId IdType="pubmed">30950096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed Ali Z., Meertens M., Fernández B., Fontova P., Vidal-Alabró A., Rigo-Bonnin R., et al. (2023). CYP3A5*3 and CYP3A4*22 cluster polymorphism effects on LCP-tac tacrolimus exposure: population pharmacokinetic approach. Pharmaceutics 15 (12), 2699. 10.3390/pharmaceutics15122699</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15122699</ArticleId><ArticleId IdType="pmc">PMC10747255</ArticleId><ArticleId IdType="pubmed">38140040</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Marcoux F., Debord J., Undre N., Rousseau A., Marquet P. (2010). Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther. Drug Monit. 32 (2), 129–135. 10.1097/FTD.0b013e3181cc70db</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FTD.0b013e3181cc70db</ArticleId><ArticleId IdType="pubmed">20110850</ArticleId></ArticleIdList></Reference><Reference><Citation>Savic R. M., Jonker D. M., Kerbusch T., Karlsson M. O. (2007). Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34 (5), 711–726. 10.1007/s10928-007-9066-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10928-007-9066-0</ArticleId><ArticleId IdType="pubmed">17653836</ArticleId></ArticleIdList></Reference><Reference><Citation>Savic R. M., Karlsson M. O. (2009). Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 11 (3), 558–569. 10.1208/s12248-009-9133-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-009-9133-0</ArticleId><ArticleId IdType="pmc">PMC2758126</ArticleId><ArticleId IdType="pubmed">19649712</ArticleId></ArticleIdList></Reference><Reference><Citation>Schijvens A. M., van Hesteren F. H. S., Cornelissen E. A. M., Bootsma-Robroeks C. M. H. H. T., Brüggemann R. J. M., Burger D. M., et al. (2019). The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatr. Nephrol. 34 (3), 507–515. 10.1007/s00467-018-4117-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-018-4117-x</ArticleId><ArticleId IdType="pmc">PMC6349786</ArticleId><ArticleId IdType="pubmed">30374607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha J., Al-Sallami H. S., Duffull S. B. (2020). An extension of janmahasatian's fat-free mass model for universal application across populations of different ethnicities. Clin. Pharmacokinet. 59 (9), 1161–1170. 10.1007/s40262-020-00883-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-020-00883-1</ArticleId><ArticleId IdType="pubmed">32201910</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnoletti G., Gargiulo A., Salerno M. P., Favi E., Pedroso J. A., Calia R., et al. (2014). Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up. Transpl. Proc. 46 (7), 2224–2227. 10.1016/j.transproceed.2014.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2014.08.003</ArticleId><ArticleId IdType="pubmed">25242756</ArticleId></ArticleIdList></Reference><Reference><Citation>Staatz C. E., Tett S. E. (2004). Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43 (10), 623–653. 10.2165/00003088-200443100-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200443100-00001</ArticleId><ArticleId IdType="pubmed">15244495</ArticleId></ArticleIdList></Reference><Reference><Citation>Staatz C. E., Tett S. E. (2015). Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clin. Pharmacokinet. 54 (10), 993–1025. 10.1007/s40262-015-0282-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-015-0282-2</ArticleId><ArticleId IdType="pubmed">26038096</ArticleId></ArticleIdList></Reference><Reference><Citation>Størset E., Holford N., Hennig S., Bergmann T. K., Bergan S., Bremer S., et al. (2014b). Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br. J. Clin. Pharmacol. 78 (3), 509–523. 10.1111/bcp.12361</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12361</ArticleId><ArticleId IdType="pmc">PMC4243902</ArticleId><ArticleId IdType="pubmed">25279405</ArticleId></ArticleIdList></Reference><Reference><Citation>Størset E., Holford N., Midtvedt K., Bremer S., Bergan S., Åsberg A. (2014a). Importance of hematocrit for a tacrolimus target concentration strategy. Eur. J. Clin. Pharmacol. 70 (1), 65–77. 10.1007/s00228-013-1584-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-013-1584-7</ArticleId><ArticleId IdType="pmc">PMC3889505</ArticleId><ArticleId IdType="pubmed">24071959</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay S., Alloway R. R. (2017). Clinical evaluation of modified release and immediate release tacrolimus formulations. AAPS J. 19 (5), 1332–1347. 10.1208/s12248-017-0119-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-017-0119-z</ArticleId><ArticleId IdType="pubmed">28717926</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataramanan R., Swaminathan A., Prasad T., Jain A., Zuckerman S., Warty V., et al. (1995). Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29 (6), 404–430. 10.2165/00003088-199529060-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-199529060-00003</ArticleId><ArticleId IdType="pubmed">8787947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlodarczyk Z., Squifflet J. P., Ostrowski M., Rigotti P., Stefoni S., Citterio F., et al. (2009). Pharmacokinetics for once versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am. J. Transpl. 9 (11), 2505–2513. 10.1111/j.1600-6143.2009.02794.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2009.02794.x</ArticleId><ArticleId IdType="pubmed">19681813</ArticleId></ArticleIdList></Reference><Reference><Citation>Woillard J. B., de Winter B. C., Kamar N., Marquet P., Rostaing L., Rousseau A. (2011). Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. Br. J. Clin. Pharmacol. 71 (3), 391–402. 10.1111/j.1365-2125.2010.03837.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2010.03837.x</ArticleId><ArticleId IdType="pmc">PMC3045548</ArticleId><ArticleId IdType="pubmed">21284698</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaoka K., Nakagawa T., Uno T. (1978). Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6 (2), 165–175. 10.1007/BF01117450</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01117450</ArticleId><ArticleId IdType="pubmed">671222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H. J., Li D. Y., Zhu H. J., Fang Y., Liu T. S. (2017). Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J. Clin. Pharm. Ther. 42 (4), 425–432. 10.1111/jcpt.12523</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.12523</ArticleId><ArticleId IdType="pubmed">28401703</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C. Y., Jiao Z., Mao J. J., Qiu X. Y. (2016). External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br. J. Clin. Pharmacol. 81 (5), 891–907. 10.1111/bcp.12830</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12830</ArticleId><ArticleId IdType="pmc">PMC4834594</ArticleId><ArticleId IdType="pubmed">26574188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Fakhoury M., Baudouin V., Storme T., Maisin A., Deschênes G., et al. (2013). Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. Eur. J. Clin. Pharmacol. 69 (2), 189–195. 10.1007/s00228-012-1330-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-012-1330-6</ArticleId><ArticleId IdType="pubmed">22706623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>